Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: J Clin Neurosci. 2018 Jul 21;56:163–168. doi: 10.1016/j.jocn.2018.06.005

Figure 4. Tumor specific killing can be achieved with CED of CAR T cells in LVHydrogel.

Figure 4

A cytotoxicity assay was utilized to evaluate the killing capacity of CAR T cells resuspended in saline or LVHydrogel. A) CAR T cells were submitted to the CED procedure and the infusate was collected at the end of the 5 hours infusion procedure and cocultured with Chromiun51 labelled U87MG.ΔEGFR glioma cells expressing the CAR T cell target antigen. CAR T cells resuspended in Fresh saline or LVHydrogel were prepared right before coculture with the glioma tumor cells. B) To determine whether the tumor cell killing seen in the LVHydrogel group retain CAR T cell specificity U87MG glioma cells lacking the EGFRvIII antigen were utilized and compared to those containing U87MG.ΔEGFR. For both cytotoxicity assays CAR T cells and glioma tumor cells were cocultured at a 10:1 ratio for at 4 hours at 37°C. Supernatant was collected and Chromiun51 was measure. Tumor specific cytotoxicity (%) = ((sample lysis ‒ spontaneous)/ (maximum lysis ‒ spontaneous)) × 100. Statistical analysis was performed using 2-way ANOVA model. Significance was determined at the level of *p < 0.05, ***p< 0.0001.